CAR T-cell Therapy Articles

Dramatic Improvement in NHL Outcomes With CAR T-Cell Versus Standard Therapy
Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel significantly improved outcomes in refractory non-Hodgkin lymphoma compared with standard therapies.
CAR T-Cell Therapy Active in High-Risk, Refractory CLL
Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014. 
Expert Discusses Approval of First CAR T-Cell Therapy
James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.
FDA Puts Clinical Holds on
The FDA placed clinical holds on 2 phase I trials investigating a gene-edited allogeneic CAR T-cell (UCART) therapy known as UCART123.
Novartis Sets a Price of $475,000 for CAR T-Cell Therapy
Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists.
FDA OKs Tisagenlecleucel in ALL as First Approved CAR T-Cell Therapy
The FDA issued a historic approval of the first chimeric antigen receptor (CAR) T-cell therapy, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.
Gilead Acquires Kite Pharma in $11.9 Billion Deal
Gilead has announced plans to acquire Kite Pharma for $180.00 per share in cash, totaling approximately $11.9 billion.
Kumar Discusses Latest Developments in Myeloma
Shaji Kumar, MD, discusses his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of myeloma.
Speculation Mounts About Price Tag for Emerging CAR Therapies
Chimeric antigen receptor (CAR) T-cell therapies could spawn a new and lucrative industry in anticancer immunotherapy, resulting in single-infusion treatments costing hundreds of thousands of dollars, and even attracting medical tourism from abroad, where regulatory permissions are likely to come more slowly than in the United States.
CAR T Cells Show Promise in Relapsed/Refractory Hodgkin Lymphoma, ALCL
Researchers have determined that CD30-specific CAR T cells could be used safely and induce durable complete responses in patients with Hodgkin lymphoma and anaplastic large cell lymphoma. 
Publication Bottom Border
Border Publication